Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Common Equity (2022 - 2025)

Historic Common Equity for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $73.7 million.

  • Axsome Therapeutics' Common Equity fell 2063.66% to $73.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.7 million, marking a year-over-year decrease of 2063.66%. This contributed to the annual value of $57.0 million for FY2024, which is 7014.56% down from last year.
  • Per Axsome Therapeutics' latest filing, its Common Equity stood at $73.7 million for Q3 2025, which was down 2063.66% from $73.1 million recorded in Q2 2025.
  • Axsome Therapeutics' 5-year Common Equity high stood at $278.8 million for Q2 2023, and its period low was $14.7 million during Q1 2022.
  • In the last 4 years, Axsome Therapeutics' Common Equity had a median value of $102.9 million in 2024 and averaged $116.3 million.
  • Its Common Equity has fluctuated over the past 5 years, first skyrocketed by 173430.18% in 2023, then plummeted by 7014.56% in 2024.
  • Axsome Therapeutics' Common Equity (Quarter) stood at $109.6 million in 2022, then surged by 74.32% to $191.0 million in 2023, then plummeted by 70.15% to $57.0 million in 2024, then increased by 29.31% to $73.7 million in 2025.
  • Its Common Equity stands at $73.7 million for Q3 2025, versus $73.1 million for Q2 2025 and $53.2 million for Q1 2025.